source
- Scribe Therapeutics upsizes IPO to $128.7 million to fund lipid-lowering gene therapyScribe Therapeutics announced pricing its initial public offering at $128.7 million, surpassing the $96 million target it had set earlier in the week. The company sold 8.6 million shares at $15 ea…
- Baxter voluntarily recalls Cefazolin in Dextrose injection after cardboard particles foundBaxter International announced a voluntary nationwide recall of Lot LD175708 of its Cefazolin in Dextrose Injection, a single-dose infusion bag. The recall follows a report that cardboard particle…